On November 3, 2020, the Board of Directors of Processa Pharmaceuticals Inc. appointed Dr. Khalid Islam to its Board of Directors, effective immediately. Dr. Islam, age 65, is an advisor to the venture group Kurma Biofund (Paris). He is currently chairman of the boards of directors of Fennec Pharmaceuticals Inc., Gain Therapeutics Inc. and Minoryx Therapeutics SL. He also serves on the board of Immunomedics Inc. and previously served as the chairman and CEO of Gentium S.p.A. from 2009-2014. Dr. Islam is also a director and shareholder of Elion Oncology, Inc. On November 3, 2020, Patrick Lin, resigned from the Board of Directors for personal reasons. Mr. Lin’s resignation was not the result of any disagreement between the Company and him on any matter relating to the Company’s operations, policies or practices and he will continue in his role as Chief Business Strategy Officer.